Home / Products / Neurological Diseases / Multiple Sclerosis

Multiple Sclerosis


Available treatments for Multiple Sclerosis
You can order a treatment for Multiple Sclerosis via TheSocialMedwork if it has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.
pill
View Product

Mavenclad

(cladribine)

by: Merck Serono
for: Multiple Sclerosis
from: 2640.32
• EMA approved (EU)
• TGA approved (AUS)

drip
View Product

Ocrevus

(ocrelizumab)

by: Roche
for: Multiple Sclerosis
from: 8418.25
• FDA approved (USA)
• TGA approved (AUS)

injection
View Product

Zinbryta

(daclizumab)

by: Biogen Idec Ltd
for: Multiple Sclerosis
from: 2107.35
• EMA approved (EU)
• FDA approved (USA)
• TGA approved (AUS)

unknown
Enquire now

We may still be able to get it for you, provided that:

• it hasn't been approved and/or isn't available in your country
• you and your treating doctor have evaluated that the medicine is suitable for you, and your doctor writes a prescription for it.


About multiple sclerosis

Multiple Sclerosis (MS) is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body [1]. The body’s immune system incorrectly attacks and damages the protective sheath around the nerve cells in the central nervous system (the brain and spinal cord) [2]. For most people with MS, episodes of worsening function (relapses) are initially followed by recovery periods (remissions). This type of MS is called relapsing MS (RMS). Over time, recovery may be incomplete, leading to progressive decline in function and increased disability [1]. Another type of MS, the primary progressive MS (PPMS) is characterized by steadily worsening function from the onset of symptoms, often without early relapses or remissions. It is estimated that about 15 % of MS patients have PPMS [3].

It is among the most common causes of neurological disability in young adults and occurs more frequently in women than men. Most people experience their first symptoms of MS between the ages of 20 and 40 [1]. It is estimated that about 2.5 million people around the world have MS [4].

The above products may be suitable for treating patients with MS. We recommend that you discuss the suitability of possible treatment options with your doctor. For further information please contact our support team at support@thesocialmedwork.com.


Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.



Share our website

Follow us


DISCLAIMER: The Services of TheSocialMedwork do not replace a physician-patient relationship and are not intended as medical advice. TheSocialMedwork provides patients and physicians with existing treatment options abroad and creates access to these options after the patient and physician have made a professional decision. Privacy Policy / Terms and Conditions
Our service uses cookies.